Read by QxMD icon Read

sindrome mielodisplasico

Xavier Calvo, Leonor Arenillas, Elisa Luño, Leonor Senent, Montserrat Arnan, Fernando Ramos, Carme Pedro, Mar Tormo, Julia Montoro, María Díez-Campelo, María Laura Blanco, Beatriz Arrizabalaga, Blanca Xicoy, Santiago Bonanad, Andrés Jerez, Meritxell Nomdedeu, Ana Ferrer, Guillermo F Sanz, Lourdes Florensa
The Revised International Prognostic Scoring System (IPSS-R) has been recognized as the score with the best outcome prediction capability in MDS, but this brought new concerns about the accurate prognostication of patients classified into the intermediate risk category. The correct enumeration of blasts is essential in prognostication of MDS. Recent data evidenced that considering blasts from nonerythroid cellularity (NECs) improves outcome prediction in the context of IPSS and WHO classification. We assessed the percentage of blasts from total nucleated cells (TNCs) and NECs in 3924 MDS patients from the GESMD, 498 of whom were MDS with erythroid predominance (MDS-E)...
July 2017: American Journal of Hematology
Leonor Arenillas, Xavier Calvo, Elisa Luño, Leonor Senent, Esther Alonso, Fernando Ramos, María Teresa Ardanaz, Carme Pedro, Mar Tormo, Víctor Marco, Julia Montoro, María Díez-Campelo, Salut Brunet, Beatriz Arrizabalaga, Blanca Xicoy, Rafael Andreu, Santiago Bonanad, Andrés Jerez, Benet Nomdedeu, Ana Ferrer, Guillermo F Sanz, Lourdes Florensa
PURPOSE: WHO classification of myeloid malignancies is based mainly on the percentage of bone marrow (BM) blasts. This is considered from total nucleated cells (TNCs), unless there is erythroid-hyperplasia (erythroblasts ≥ 50%), calculated from nonerythroid cells (NECs). In these instances, when BM blasts are ≥ 20%, the disorder is classified as erythroleukemia, and when BM blasts are < 20%, as myelodysplastic syndrome (MDS). In the latter, the percentage of blasts is considered from TNCs...
September 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
David Valcárcel, Guillermo Sanz, Margarita Ortega, Benet Nomdedeu, Elisa Luño, María Diez-Campelo, María Teresa Ardanaz, Carmen Pedro, Julía Montoro, Rosa Collado, Rafa Andreu, Victor Marco, María Teresa Cedena, Raquel de Paz, Mar Tormo, Blanca Xicoy, Fernando Ramos, Joan Bargay, Bernardo Gonzalez, Salut Brunet, Juan Antonio Muñoz, Valle Gomez, Alicia Bailén, Joaquin Sanchez, Brayan Merchán, Consuelo del Cañizo, Teresa Vallespí
BACKGROUND: We aimed to compare the ability of recently developed prognostic indices for myelodysplastic syndromes to identify patients with poor prognoses within the lower-risk (low and intermediate-1) categories defined by the International Prognosis Scoring System (IPSS). METHODS: We included patients with de-novo myelodysplastic syndromes diagnosed between Nov 29, 1972, and Dec 15, 2011, who had low or intermediate-1 IPSS scores and were in the Spanish Registry of Myelodysplastic Syndromes...
June 2015: Lancet Haematology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"